Aequus and Ehave venture into collaboration agreement for bioinformatics platform

In a bid to enhance and streamline data management processes for Aequus– sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders, Aequus Pharmaceuticals which is a specialty pharmaceutical company aiming to develop and advance promotion of differentiated products and Ehave which is a healthcare bioinformatics company whose platform efficiently captures, integrates and delivers high -quality clinical data  have ventured into a collaboration agreement wherein Aequus will incorporate Ehave‘s bioinformatics platform to accentuate and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. E

Doug Janzen, Chairman and CEO of Aequus said “Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original Letter of Intent with Ehave. We have a number of different trials in late-stage planning and see multiple opportunities for us to leverage our traditional pharmaceutical expertise in designing and implementing clinical programs, but we also see growing opportunities for us to leverage our existing relationships with Canadian clinicians and take advantage of our existing pharmaceutical sales infrastructure to better serve clinicians and Insurers as it relates to medical cannabis. We and Ehave are in a unique position to generate meaningful product safety and efficacy data in a variety of trial settings in a very efficient and cost-effective way.”